prazosin and Anxiety
prazosin has been researched along with Anxiety in 14 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-four individuals seeking treatment for AUD participated in a six-week placebo-controlled study of prazosin and underwent an anticipatory anxiety task during fMRI scans at baseline and three weeks." | 9.34 | Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder. ( Adinoff, B; Bogenschutz, M; Boggs, KM; Clifford, J; Eck, M; Ling, J; Mayer, AR; Wilcox, CE; Witkiewitz, K, 2020) |
| "Prazosin treatment before stresses experienced during alcohol deprivations may prevent the increased anxiety during subsequent deprivation/abstinence that is a risk factor for relapse to alcohol drinking." | 7.85 | Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2017) |
| "The findings indicate that alcohol withdrawal symptoms are a significant moderator of prazosin treatment response for alcohol use outcomes and for associated symptoms of alcohol craving, anxiety, and mood symptoms." | 5.41 | Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms. ( Angarita, GA; Fogelman, N; Fox, HC; Hermes, G; Milivojevic, V; Morgan, PM; Sinha, R; Wemm, S, 2021) |
| "Thirty-four individuals seeking treatment for AUD participated in a six-week placebo-controlled study of prazosin and underwent an anticipatory anxiety task during fMRI scans at baseline and three weeks." | 5.34 | Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder. ( Adinoff, B; Bogenschutz, M; Boggs, KM; Clifford, J; Eck, M; Ling, J; Mayer, AR; Wilcox, CE; Witkiewitz, K, 2020) |
| "Prazosin may attenuate stress cue-induced alcohol craving and anxiety during early abstinence while improving adrenergic and stress system function, effects which are independent of a history of lifetime anxiety disorders." | 5.34 | Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder. ( Angarita, GA; Fox, HC; Hermes, G; Milivojevic, V; Sinha, R, 2020) |
| "Prazosin appears efficacious in decreasing stress- and cue-induced alcohol craving and may normalize the stress dysregulation associated with early recovery from alcoholism." | 5.16 | Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. ( Anderson, GM; Fox, HC; Hansen, J; Kimmerling, A; Morgan, PT; Siedlarz, KM; Sinha, R; Tuit, K, 2012) |
| " CIE/FSS treatment increased anxiety, which was blocked by treatment with the α1-AR inverse agonist prazosin." | 3.96 | Noradrenergic tone mediates marble burying behavior after chronic stress and ethanol. ( Blandino, KL; den Hartog, CR; Grampetro, MA; Moorman, DE; Nash, ML; Sjogren, ER; Vazey, EM, 2020) |
| "Prazosin treatment before stresses experienced during alcohol deprivations may prevent the increased anxiety during subsequent deprivation/abstinence that is a risk factor for relapse to alcohol drinking." | 3.85 | Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations. ( Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2017) |
| "In the present study, the effect of alpha-adrenoceptor agents on response to nicotine in an anxiety model (elevated plus-maze) in mice was investigated." | 3.70 | Involvement of adrenergic and cholinergic systems in nicotine-induced anxiogenesis in mice. ( Babaie, A; Etminani, A; Gharib, B; Homayoun, H; Zarrindast, MR, 2000) |
| "Post-traumatic stress disorder (PTSD) is a severe chronic mental illness that develops in individuals exposed to life-threatening trauma and is characterized by hyperarousal, flashbacks and nightmares." | 1.56 | The serotonergic and alpha-1 adrenergic receptor modulator ACH-000029 ameliorates anxiety-like behavior in a post-traumatic stress disorder model. ( Azevedo, H; Ferreira, M; Mascarello, A; Osten, P; Werneck Guimarães, CR, 2020) |
Research
Studies (14)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Azevedo, H | 1 |
| Ferreira, M | 1 |
| Mascarello, A | 1 |
| Osten, P | 1 |
| Werneck Guimarães, CR | 1 |
| Wilcox, CE | 1 |
| Adinoff, B | 1 |
| Clifford, J | 1 |
| Ling, J | 1 |
| Witkiewitz, K | 1 |
| Mayer, AR | 1 |
| Boggs, KM | 1 |
| Eck, M | 1 |
| Bogenschutz, M | 1 |
| Milivojevic, V | 2 |
| Angarita, GA | 2 |
| Hermes, G | 2 |
| Sinha, R | 3 |
| Fox, HC | 3 |
| den Hartog, CR | 1 |
| Blandino, KL | 1 |
| Nash, ML | 1 |
| Sjogren, ER | 1 |
| Grampetro, MA | 1 |
| Moorman, DE | 1 |
| Vazey, EM | 1 |
| Wemm, S | 1 |
| Fogelman, N | 1 |
| Morgan, PM | 1 |
| Lucas, EK | 1 |
| Wu, WC | 1 |
| Roman-Ortiz, C | 1 |
| Clem, RL | 1 |
| Palotai, M | 1 |
| Telegdy, G | 2 |
| Tanaka, M | 1 |
| Bagosi, Z | 1 |
| Jászberényi, M | 1 |
| Skelly, MJ | 2 |
| Weiner, JL | 2 |
| Chappell, AE | 1 |
| Carter, E | 1 |
| Rasmussen, DD | 1 |
| Kincaid, CL | 1 |
| Froehlich, JC | 1 |
| Anderson, GM | 1 |
| Tuit, K | 1 |
| Hansen, J | 1 |
| Kimmerling, A | 1 |
| Siedlarz, KM | 1 |
| Morgan, PT | 1 |
| Schally, AV | 1 |
| Przegaliński, E | 1 |
| Filip, M | 1 |
| Chojnacka-Wójcik, E | 1 |
| Tatarczyńska, E | 1 |
| Zarrindast, MR | 1 |
| Homayoun, H | 1 |
| Babaie, A | 1 |
| Etminani, A | 1 |
| Gharib, B | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prazosin Treatment for Alcohol Use Disorder With Alcohol Withdrawal Symptoms[NCT04793685] | Phase 1/Phase 2 | 150 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | ||
| Open Label 8-Week Study of Prazosin Use in Adults With Anxiety Disorders[NCT03894345] | Phase 1 | 20 participants (Anticipated) | Interventional | 2019-05-24 | Suspended (stopped due to COVID-19) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trials
4 trials available for prazosin and Anxiety
| Article | Year |
|---|---|
Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adult; Alcoholism; Anticipation, Psychological; | 2020 |
Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenocorticotropic Hormone; Adult; Alcoholism; Anxiety; An | 2020 |
Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Alcohol Abstinence; Alcoholism; Anxiety; Central Ner | 2021 |
Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Alcoholism; Anxiety; Blood Pressure; Cues; Diagnosti | 2012 |
Other Studies
10 other studies available for prazosin and Anxiety
| Article | Year |
|---|---|
The serotonergic and alpha-1 adrenergic receptor modulator ACH-000029 ameliorates anxiety-like behavior in a post-traumatic stress disorder model.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Anti-Anxiety Agents; Anxiety; Brain Chemistry; Gen | 2020 |
Noradrenergic tone mediates marble burying behavior after chronic stress and ethanol.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Animals; Anxiety; Ethanol; Female; Locus | 2020 |
Prazosin during fear conditioning facilitates subsequent extinction in male C57Bl/6N mice.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Anxiety; Basolateral Nuclear Complex; Conditioning | 2019 |
Neuropeptide AF induces anxiety-like and antidepressant-like behavior in mice.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antidepressive Agent | 2014 |
Chronic treatment with prazosin or duloxetine lessens concurrent anxiety-like behavior and alcohol intake: evidence of disrupted noradrenergic signaling in anxiety-related alcohol use.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Uptake Inhibitors; Alcohol Drinking; Animals; An | 2014 |
Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling.
Topics: Aging; Alcohol Drinking; Animals; Anti-Anxiety Agents; Anxiety; Central Nervous System Depressants; | 2015 |
Prazosin Prevents Increased Anxiety Behavior That Occurs in Response to Stress During Alcohol Deprivations.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Animals; Anxiety; Dose-Response Relations | 2017 |
Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Avoidance Learning; Bicuculline; Cyproh | 2012 |
The role of 5-hydroxytryptamine1A (5-HT1A) receptors in the anticonflict activity of beta-adrenoceptor antagonists.
Topics: Adrenergic beta-Antagonists; Animals; Anxiety; Betaxolol; Conflict, Psychological; Disease Models, A | 1994 |
Involvement of adrenergic and cholinergic systems in nicotine-induced anxiogenesis in mice.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Anxiety; Atropine; Clonidine; Hexa | 2000 |